Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FDMT NASDAQ:OKYO NASDAQ:TECX NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$6.94-0.4%$5.58$2.23▼$17.41$325.52M2.86678,483 shs624,832 shsOKYOOKYO Pharma$2.18-0.9%$2.66$0.90▼$3.35$82.74M-0.1118,019 shs13,295 shsTECXTectonic Therapeutic$17.31+0.5%$22.12$13.70▼$61.07$322.22M3.42450,966 shs393,310 shsUPXIUpexi$5.46-0.7%$6.19$1.90▼$22.57$323.89M-0.476.72 million shs6.17 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics0.00%+13.52%+23.80%+59.86%-54.30%OKYOOKYO Pharma-1.75%-5.39%-32.87%-5.79%+117.33%TECXTectonic Therapeutic+5.58%+3.42%-22.81%-26.72%-2.49%UPXIUpexi-2.83%-20.17%-8.94%-56.73%+44.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFDMT4D Molecular Therapeutics$6.94-0.4%$5.58$2.23▼$17.41$325.52M2.86678,483 shs624,832 shsOKYOOKYO Pharma$2.18-0.9%$2.66$0.90▼$3.35$82.74M-0.1118,019 shs13,295 shsTECXTectonic Therapeutic$17.31+0.5%$22.12$13.70▼$61.07$322.22M3.42450,966 shs393,310 shsUPXIUpexi$5.46-0.7%$6.19$1.90▼$22.57$323.89M-0.476.72 million shs6.17 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFDMT4D Molecular Therapeutics0.00%+13.52%+23.80%+59.86%-54.30%OKYOOKYO Pharma-1.75%-5.39%-32.87%-5.79%+117.33%TECXTectonic Therapeutic+5.58%+3.42%-22.81%-26.72%-2.49%UPXIUpexi-2.83%-20.17%-8.94%-56.73%+44.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40338.04% UpsideOKYOOKYO Pharma 3.00Buy$7.00221.10% UpsideTECXTectonic Therapeutic 3.14Buy$80.29363.81% UpsideUPXIUpexi 3.50Strong Buy$15.50183.88% UpsideCurrent Analyst Ratings BreakdownLatest OKYO, FDMT, UPXI, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025TECXTectonic TherapeuticOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$80.008/30/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating8/13/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/4/2025UPXIUpexiAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$15.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating7/21/2025TECXTectonic TherapeuticTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$64.007/12/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated Rating(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFDMT4D Molecular Therapeutics$40K8,102.45N/AN/A$11.05 per share0.63OKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/AUPXIUpexi$26M12.37N/AN/A$6.24 per share0.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)OKYOOKYO Pharma-$4.71MN/A0.00N/AN/AN/AN/AN/AN/ATECXTectonic Therapeutic-$57.98M-$4.04N/AN/AN/AN/A-30.13%-28.33%11/6/2025 (Estimated)UPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/29/2025 (Estimated)Latest OKYO, FDMT, UPXI, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/7/2025Q2 2025TECXTectonic Therapeutic-$0.98-$1.07-$0.09-$1.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFDMT4D Molecular TherapeuticsN/A8.758.75OKYOOKYO PharmaN/A0.400.40TECXTectonic TherapeuticN/A25.6025.60UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFDMT4D Molecular Therapeutics99.27%OKYOOKYO Pharma2.97%TECXTectonic Therapeutic62.63%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipFDMT4D Molecular Therapeutics9.60%OKYOOKYO Pharma40.46%TECXTectonic Therapeutic38.00%UPXIUpexi4.42%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableOKYOOKYO Pharma737.61 million22.39 millionNot OptionableTECXTectonic Therapeutic12018.71 million11.60 millionN/AUPXIUpexi13058.89 million56.29 millionOptionableOKYO, FDMT, UPXI, and TECX HeadlinesRecent News About These CompaniesSolana gains 5% as Forward Industries reveals $1.6 billion SOL treasury planSeptember 8 at 10:14 PM | fxstreet.comUpexi Engages in September 2025 Investor ConferencesSeptember 8 at 5:50 PM | tipranks.comUpexi (NASDAQ:UPXI) Stock Price Down 4.5% - What's Next?September 7 at 3:58 AM | marketbeat.comUpexi to Participate in Upcoming September ConferencesSeptember 3, 2025 | manilatimes.netMBitcoin Gains As ‘September Slump’ Remains Uncertain – Retail Traders Bet On Break From Trend In 2025September 3, 2025 | msn.comUpexi, Inc. Announces Strategic Investment in Alpha ExchangeAugust 28, 2025 | markets.businessinsider.comUpexi Invests in Alpha Exchange for Revenue ShareAugust 27, 2025 | tipranks.comUpexi Amends Securities Purchase AgreementAugust 26, 2025 | msn.comUpexi Approves Share Increase and New AgreementAugust 20, 2025 | tipranks.comUpexi (NASDAQ:UPXI) Trading Down 10% - Time to Sell?August 17, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateAugust 17, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Shares Gap Down - Here's What HappenedAugust 16, 2025 | marketbeat.comUpexi (NASDAQ:UPXI) Stock Rating Upgraded by Cantor FitzgeraldAugust 16, 2025 | marketbeat.comDigital Asset Treasury Firms Plunge as Bitcoin Tumbles Below $117K, ETH Slides to $4.4KAugust 15, 2025 | coindesk.comUpexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?August 15, 2025 | marketbeat.comFormer Amazon aggregator turns to Solana, records $70K in daily rewardsAugust 13, 2025 | msn.comUpexi establishes Advisory Committee, welcomes Hayes as first memberAugust 13, 2025 | msn.comUpexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?August 12, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)August 11, 2025 | prnewswire.comCrypto Currents: SEC eases staking rules as bitcoin miners pivot to AIAugust 6, 2025 | msn.comUpexi Surpasses 2 Million SOL in its TreasuryAugust 5, 2025 | taiwannews.com.twTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOKYO, FDMT, UPXI, and TECX Company Descriptions4D Molecular Therapeutics NASDAQ:FDMT$6.94 -0.03 (-0.43%) Closing price 04:00 PM EasternExtended Trading$6.98 +0.03 (+0.50%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.OKYO Pharma NASDAQ:OKYO$2.18 -0.02 (-0.91%) Closing price 04:00 PM EasternExtended Trading$2.19 +0.01 (+0.46%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Tectonic Therapeutic NASDAQ:TECX$17.31 +0.09 (+0.52%) Closing price 04:00 PM EasternExtended Trading$17.62 +0.31 (+1.79%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.Upexi NASDAQ:UPXI$5.46 -0.04 (-0.73%) Closing price 04:00 PM EasternExtended Trading$5.58 +0.13 (+2.29%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
